China Shineway Pharmaceutical Group Limited (HK:2877)
:2877
Want to see HK:2877 full AI Analyst Report?
2877 Stock Chart & Stats
HK$8.58
HK$0.18(2.26%)
At close: 4:00 PM EST
HK$8.58
HK$0.18(2.26%)
Day’s Range― - ―
52-Week RangeHK$7.47 - HK$10.47
Previous CloseN/A
Volume914.00K
Average Volume (3M)1.29M
Market Cap
HK$6.23B
Enterprise Value-HK$1.39B
Total Cash (Recent Filing)HK$7.57B
Total Debt (Recent Filing)HK$335.05M
Price to Earnings (P/E)5.7
Beta0.54
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.8%
Share Statistics
EPS (TTM)1.25
Shares Outstanding827,000,000
10 Day Avg. Volume1,790,900
30 Day Avg. Volume1,290,900
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.72
Price to Sales (P/S)1.86
P/FCF Ratio5.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.12
Revenue Forecast (FY)HK$4.11B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityConsistently very high gross and healthy operating margins indicate durable product economics and pricing power in core proprietary Chinese medicines. Sustained net margin near 30% supports long-term internal funding for R&D, dividends, and strategic reinvestment without reliance on external financing.
Very Low LeverageAn exceptionally conservative balance sheet with minimal debt preserves financial flexibility and reduces interest burden. Low leverage limits bankruptcy risk, supports steady dividend policy, and enables the company to pursue acquisitions or capital expenditure without straining cash flow over the medium term.
Strong Free Cash FlowRobust and positive free cash flow, including a notable rebound, demonstrates the business can convert profits into cash. This strengthens the firm's ability to sustain dividends, fund development of proprietary medicines, and absorb cyclical demand shifts without increasing leverage.
Bears Say
Declining RevenueSignificant top-line contraction indicates weakening demand or loss of market share in key product lines. Persistent revenue decline undermines scalability of high-margin franchises, pressures unit economics, and reduces headroom for investment in R&D and commercialization over the coming months.
Margin Softening From 2023 PeakErosion of operating margins from prior highs suggests structural pressure on pricing, cost inputs, or product mix. If sustained, margin compression will weaken return on capital and could force trade-offs between margin restoration and revenue-driving investments.
Cash Flow Volatility & Data GapsWhile FCF recovered, its year-to-year volatility and missing coverage metrics reduce confidence in consistent cash conversion. That uncertainty complicates forecasting of dividend sustainability and capacity to fund new product launches or marketing at prior levels without precautionary liquidity buffers.
China Shineway Pharmaceutical Group Limited News
2877 FAQ
What was China Shineway Pharmaceutical Group Limited’s price range in the past 12 months?
China Shineway Pharmaceutical Group Limited lowest stock price was HK$7.47 and its highest was HK$10.47 in the past 12 months.
What is China Shineway Pharmaceutical Group Limited’s market cap?
China Shineway Pharmaceutical Group Limited’s market cap is HK$6.23B.
When is China Shineway Pharmaceutical Group Limited’s upcoming earnings report date?
China Shineway Pharmaceutical Group Limited’s upcoming earnings report date is Sep 01, 2026 which is in 81 days.
How were China Shineway Pharmaceutical Group Limited’s earnings last quarter?
China Shineway Pharmaceutical Group Limited released its earnings results on Mar 27, 2026. The company reported HK$0.486 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.486.
Is China Shineway Pharmaceutical Group Limited overvalued?
According to Wall Street analysts China Shineway Pharmaceutical Group Limited’s price is currently Overvalued.
Does China Shineway Pharmaceutical Group Limited pay dividends?
China Shineway Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.487 which represents an annual dividend yield of 5.8%. See more information on China Shineway Pharmaceutical Group Limited dividends here
What is China Shineway Pharmaceutical Group Limited’s EPS estimate?
China Shineway Pharmaceutical Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Shineway Pharmaceutical Group Limited have?
China Shineway Pharmaceutical Group Limited has 827,000,000 shares outstanding.
What happened to China Shineway Pharmaceutical Group Limited’s price movement after its last earnings report?
China Shineway Pharmaceutical Group Limited reported an EPS of HK$0.486 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.483%.
Which hedge fund is a major shareholder of China Shineway Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:2877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Shineway Pharmaceutical Group Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.07%
12-Months-Change
Fundamentals
Return on Equity
11.97%
Trailing 12-Months
Asset Growth
12.33%
Trailing 12-Months
Company Description
China Shineway Pharmaceutical Group Limited
As an investment holding enterprise, China Shineway Pharmaceutical Group Limited is dedicated to the development, production, and sale of traditional Chinese medicines throughout the People's Republic of China and Hong Kong. Its extensive product range includes modern Chinese pharmaceuticals delivered as soft capsules, granular preparations, and injectable forms, alongside specialized Traditional Chinese Medicine (TCM) Formula Granules. These offerings cater to a broad spectrum of therapeutic needs, such as cardiovascular and cerebrovascular health, anti-viral applications, orthopedic conditions, pediatric ailments, gynecological care, and gastrointestinal issues. Furthermore, the company is involved in the trading of agricultural commodities. Founded in 2004, its headquarters are situated in Shijiazhuang, PRC, and it functions as a subsidiary of Forway Investment Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Traditional Chinese Medicine Holdings Co
―
Jacobson Pharma Corporation Limited
―
Grand Pharmaceutical Group Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―
Options Prices
Currently, No data available
---